For individuals with a family history of Crohn’s disease, a proactive dietary approach may offer a way to mitigate risk. New research presented at the European Crohn’s and Colitis Organisation (ECCO) 2026 conference suggests that a whole-food diet, known as the Tasty&Healthy (T&H) diet, can significantly reduce inflammation in those at higher risk. This finding centers around a randomized controlled trial, dubbed PIONIR, which examined the impact of dietary changes on biomarkers associated with Crohn’s disease.
The study focused on asymptomatic first-degree relatives – parents, siblings, or children – of individuals already diagnosed with Crohn’s disease. These individuals often have elevated levels of fecal calprotectin (FCP), a protein indicative of intestinal inflammation, even without exhibiting overt symptoms. Researchers screened 950 healthy first-degree relatives for elevated FCP levels, ultimately focusing on 28 participants who showed consistently high FCP but no visible signs of Crohn’s disease upon endoscopic examination. This targeted approach allowed researchers to isolate the effect of diet on early inflammatory markers.
Dietary Intervention and Calprotectin Levels
Participants were randomly assigned to either follow the T&H diet for eight weeks or maintain their usual eating habits. The T&H diet emphasizes whole, unprocessed foods, prioritizing nutrient density. After the initial eight-week period, participants switched diets for another eight weeks – a “cross-over” design that allowed researchers to compare the effects within the same individuals. The results were striking. After eight weeks on the T&H diet, participants experienced a significant reduction in FCP levels, dropping from a median of 211 μg/g to 45 μg/g, compared to 112 μg/g in the control group (p = 0.047).
Notably, over half (54%) of those following the T&H diet achieved an FCP level below 50 μg/g after eight weeks, compared to just 20% in the control group. The relative risk was 1.73 (95% confidence interval 0.92-3.3; p = 0.09). When the control group transitioned to the T&H diet during the cross-over phase, their FCP levels also decreased, while those who reverted to their usual diet saw their inflammation markers rise again. Across the entire cross-over dataset, FCP levels were 37% lower with the T&H diet compared to the control diet (p < 0.001).
Understanding Fecal Calprotectin and Crohn’s Disease Risk
Fecal calprotectin is a key biomarker used to assess inflammation in the intestines. Elevated levels can indicate the presence of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. While not a definitive diagnosis on its own, FCP levels aid doctors determine whether further investigation, such as colonoscopy, is warranted. The PIONIR study’s focus on individuals with elevated FCP but no endoscopic evidence of disease is significant, as it suggests that dietary intervention may be able to prevent the progression to full-blown Crohn’s disease in those identified as being at risk. The increasing prevalence of IBD underscores the importance of exploring preventative strategies for those with a genetic predisposition.
The Tasty&Healthy Diet: What Does It Entail?
While specific details of the T&H diet weren’t fully outlined in the presented research, the study indicates it centers around whole, unprocessed foods. This approach aligns with growing evidence supporting the role of diet in modulating gut health, and inflammation. The researchers emphasized that the T&H diet was a “volwaardige voeding” – meaning it provided complete nutrition. Further research is needed to pinpoint the specific components of the diet that contribute to its beneficial effects and to determine its long-term sustainability.
Implications for Prevention and Future Research
The findings from the PIONIR trial offer a promising avenue for preventing Crohn’s disease in high-risk individuals. The study suggests that a relatively simple intervention – adopting a whole-food diet – can have a measurable impact on intestinal inflammation. Although, it’s important to note that this research was conducted on a relatively small group of participants (28 individuals). Larger, long-term studies are needed to confirm these findings and to determine the optimal duration and composition of the T&H diet. Researchers are also exploring novel biomarkers to guide therapy in chronic inflammatory conditions like Crohn’s disease.
The next step in this research will likely involve larger-scale trials to assess the long-term effects of the T&H diet on the development of Crohn’s disease. Researchers will also need to investigate whether the diet is effective in different populations and whether it can be tailored to individual needs. The ECCO Congress 2026 also featured research on subcutaneous infliximab (Remsima SC) for managing Crohn’s and colitis, highlighting the ongoing efforts to improve treatment options for these conditions. Data presented showed that subcutaneous infliximab can effectively maintain disease control even after a treatment pause.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have thoughts on this research? Share your comments below, and please consider sharing this article with anyone who might find it helpful.
